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Introduction
Acute promyelocytic leukemia (APL) comprises 10% of cases 
of de novo acute myeloid leukemia (AML) and is characterized 
by a balanced translocation involving the RARA gene, most 
frequently the t(15;17)(q22;q12) (1). Rarely, APL can occur 
as a secondary leukemia after therapy for another malignancy 
(t-APL) (2-4). APL has a distinct morphology, including 
promyelocytes with prominent azurophilic granules (5), and 
a distinct immunophenotype (most often CD13+, CD33+, 
CD117+, CD34−, HLA-DR−) (6) compared with other 
subtypes of AML. The prognosis for patients with APL 
is excellent overall, however, many patients die within the 
first week of therapy due to complications of disseminated 
intravascular coagulation (1). It is imperative that the 
diagnosis of APL be made promptly and treatment initiated 
immediately in order to prevent this complication.
Currently we present the case of a woman who presented 
with pancytopenia after chemotherapy for breast cancer. 
The presence of CD34+ blasts misled the referring 
physicians into considering a diagnosis of therapy related 
AML (t-AML).
Case presentation
A 61-year-old woman presented in November 2015 with 
complaints of fatigue and an unresolving sinus infection. 
A complete blood count (CBC) showed a white blood 
count (WBC) of 500/mm3, a hemoglobin of 4.6 g/dL and 
a platelet count of 28,000/mm3. The patient had a prior 
history of stage IIB, T2N1, estrogen receptor positive, 
progesterone receptor positive, HER2/neu negative, 
poorly differentiated invasive ductal carcinoma of the 
right breast diagnosed in 2011 that was treated with 
bilateral mastectomy and axillary lymph node dissection. 
Postoperative chemotherapy consisted of 4 cycles of 
dose dense Adriamycin and cyclophosphamide followed 
by 4 cycles of paclitaxel and then radiation therapy. The 
patient was currently receiving anastrozole. She also had a 
history of hypertension and paroxysmal atrial fibrillation. 
The patient had a bone marrow aspiration and biopsy 
performed by a radiologist at an outside institution. The 
aspirate smears were hemodilute and markedly hypocellular. 
Rare hypergranular promyelocytes were noted. On flow 
cytometry, 4% of the cells were immature myeloid cells 
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with the immunophenotype CD34+, CD117+, CD13+, and 
CD33+. The core biopsy was markedly hypercellular (>95%) 
with CD34+ myeloblasts representing 60–70% of the cells 
present. The patient was transferred to us for therapy. 
Upon evaluation at our institution the WBC was 
1300/mm3, the hemoglobin (post transfusion) was 8.7 g/dL, 
and the platelet count was 19,000/mm3. There were 
13% neutrophils, 69% lymphocytes, 1% eosinophils, 
1% basophils and 16% blasts in the peripheral blood. 
The prothrombin time was 12.2 s, the activated partial 
thromboplastin time was 24.6 s and the fibrinogen was 
256 mg/dL. D-dimers were present at a level of greater 
than 35.2 mg/L.
Due to the presence of pancytopenia and an abnormal 
coagulation profile, all-trans retinoic acid (ATRA) 
was immediately administered to the patient pending 
clarification of her diagnosis. A bone marrow aspirate at our 
institution showed that the smears were cellular with 50% 
abnormal promyelocytes and 23% myeloblasts (Figure 1). 
The promyelocytes and blasts were mostly intermediate in 
size with scant to moderate cytoplasm; some had cytoplasmic 
granules and blebs and some had bilobed nuclei. Flow 
cytometry demonstrated an abnormal immature myeloid 
population (37% of total) that was CD13+, CD33+, CD34+ 
and CD117+ with aberrant expression of CD2 while negative 
for HLA-DR, CD11b, CD11c and CD56 (Figure 2). 
The bone marrow core was hypercellular (90%) and was 
infiltrated with sheets of immature myeloid precursors and 
blasts that were large to intermediate in size with moderate 
cytoplasm, round to slightly irregular nuclear contour and 
fine chromatin. FISH demonstrated the PML-RARA fusion 
in 142 of 200 cells. PML-RAR fusions transcripts were 
detected by RT-PCR at a level of 0.15738. Cytogenetics 
subsequently demonstrated 46,XX,t(15;17)(q24;q21)
[16]/46,idem,del(X)(p11.3),add(3)(q29),t(4;5)(q31;q11.2)
[3]/46,XX[1]. No molecular abnormalities were detected on 
an MDS/AML nextgen sequencing panel. 
The patient received induction therapy with ATRA, 
idarubicin 12 mg/m2 daily times 3 and cytarabine 100 mg/m2 
IV continuous infusion times 7 days. Her induction 
was uneventful including no evidence of differentiation 
syndrome. She obtained complete remission by day 35 
of therapy. She is currently receiving a planned course 
of consolidation therapy with chemotherapy, ATRA and 
arsenic trioxide. 
Discussion
As cancer therapies have improved, more patients are 
surviving their first cancer and thus are at risk of developing 
long term complications such as t-AML. Most cases of 
t-AML can be categorized into one of two broad categories. 
In the first, patients present 1–3 years after their initial 
therapy, have no antecedent cytopenias, and typically have 
cytogenetic abnormalities involving chromosome 11q23 (7). 
In the other group, patients present 3–5 years after therapy, 
have a myelodysplastic phase, and frequently have poor risk 
cytogenetics including −5, −7 and complex abnormalities (8). 
Breast cancer survivors are at relatively high risk for the 
development of t-AML, in part due to their excellent 
prognosis for surviving their breast cancer (9). In an 
NSAPB report, patients who had received dose intensive 
Adriamycin and cyclophosphamide plus growth factor had 
a risk of 1.01% at 5 years (10). The addition of radiation 
further increased the risk of t-AML (relative risk, 2.38).
Most patients with t-AML have a poor prognosis (11). 
However patients with good risk cytogenetics can have 
a prognosis similar to that of de novo patients. In a study 
of 206 patients with therapy-related myeloid neoplasms 
(t-MN) reported by Larson the median survival was 
7–9 months overall, however it was 27 months in patients 
with favorable cytogenetics (12). In a GIMEMA study of 
51 patients with t-APL (13), the complete remission, 4-year 
event-free survival, and 4-year overall survival rates were 
97% vs. 93%, 65% vs. 68%, and 85% vs. 78% for the t-APL 
and de novo APL groups, respectively, after therapy with 
the AIDA regimen. In another study of 106 t-APL patients 
(60 of who had prior breast cancer) the actuarial survival at 
Figure 1 Bone marrow aspirate shows abnormal promyelocytes 
and myeloblasts. They are mostly large in size with variable 
cytoplasm, some with cytoplasmic granules, round to irregular 
nuclei (some bilobed), fine chromatin and often prominent nucleoli 
(Giemsa, 100×). 
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8 years was 59% after either an anthracycline and 
cytarabine-based regimen or ATRA combined with 
chemotherapy (14). However, in a more recent report, 
patients with t-APL had an inferior CR rate (63.6% 
vs. 92.5%, P=0.008), largely due to a higher induction 
mortality rate (2). Although there were no cases of leukemic 
resistance in either group in the latter study, the increased 
induction mortality translated into an inferior overall 
survival rate (51% vs. 84%, P<0.005).
Classically, APL cells are CD13+, CD33+, CD117+, 
CD34−, and HLA-DR−, however this immunophenotype is 
not present in all cases (5). Gorczyca et al. described four 
distinct patterns in 97 cases of APL (15). The majority of 
cases (classical hypergranular APL) were characterized by 
high side scatter (SSC), CD117+, CD34−, heterogeneous 
CD13+ and bright CD33+. The second most common type 
(microgranular) differed from classical APL by low SSC, 
and frequent coexpression of CD2 and CD34. Rare cases 
showed a mixture of neoplastic cells (low SSC/CD2+/
CD13+/CD34+/CD117+) and a prominent population of 
benign granulocytes and maturing myeloid precursors. 
A final subtype showed two APL populations, one with 
hypogranular and one with hypergranular characteristics. 
In some reports (16), as many as one third of APL patients 
are CD34+. These patients most often have hypogranular 
morphology and a higher WBC at presentation. In a report 
by Liang et al., the median WBC was 25,900/mm3 for 
patients with CD34+ APL compared with 5,300/mm3 for 
patients with CD34− APL (17). Although this author found 
no difference in the induction CR rate, others have found 
that CD34 expression was significantly associated with a 
decreased incidence of molecular remission (16), increased 
incidence of early death (16), as well as decreased disease free 
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Figure 2 Flow cytogram shows abnormal dim CD45 positive immature myeloid population with moderate side scatter expressing CD13, 
CD33, CD34 and CD117 while negative for HLA-DR.
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cells can be variably responsive to ATRA, suggesting that 
chemotherapy might still be necessary in these patients (19).
The presence of CD34+ cells and hypogranular morphology 
can mislead the physician. Mohamed et al. reported a 
patient with pancytopenia whose bone marrow morphology 
demonstrated 90% blasts that were mostly agranular with no 
Auer rods (20). Flow cytometry demonstrated that the cells 
were CD13+, CD33+, CD117+ and MPO+, as well as CD34+ 
and HLA-DR+. The patient started standard treatment 
for AML, but the therapy was changed after cytogenetics 
demonstrated t(15;17)(q22;q12). Our patient was similar to 
theirs, however ours was more misleading because the history 
of prior treatment for breast cancer led the physicians to 
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